GOG 153, 2004

Question 1

Study question for GOG 153?

Answer 1

Estimate the objective response rate and toxicity with alternative megestrol acetate (MA) and tamoxifen citrate (T) with ECa

Question 2

Study design of GOG 153?

Answer 2

Prospective; megace 80 mg PO BID for 3 weeks then tamoxifen 20 mg PO BID for 3 weeks until PD or AE

Question 3

Inclusion criteria for GOG 153?

Answer 3

Recurrent or advanced ECa, no prior cytotoxic or hormonal therapy; could have RT if >6 weeks p/t PD

Question 4

Results of GOG 153?

Answer 4

n=61 (n=56 evaluated); 12 CR and 2 PR, ORR 27% with G1, 24% with G2 and 22% with G3; Improved response if younger, extra pelvic disease. 2 pt with VTE